Search results
Found 2364 matches for
University of Oxford and AstraZeneca researchers present a pooled analysis of Phase 3 trials of a vaccine against SARS-CoV-2 across two different dose regimens, resulting in an average efficacy of 70.4%.
Daniel O'Connor
Researchers
BSc AFHEA MSc DPhil (OXON) Daniel O'Connor - Associate Professor | Head of Bioinformatics
Yama G.Farooq
Researchers
BCA Computer Application , MSc in Information Technology and Software Engineering Yama G.Farooq - Programming and Data Management Director
Stephane Paulus
Researchers
MD, DTM&H, FRCPCH Stephane Paulus - Consultant in Paediatric Infectious Diseases
Sir Andrew Pollard
Researchers
BSc MBBS PhD (Lond), DIC, MRCP (UK), FHEA, FRCPCH, MA, FMedSci Sir Andrew Pollard - Ashall Professor of Infection & Immunity
Sofia Scherrer
Researchers
Sofia Scherrer - Paediatric Clinical Research Fellow